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Selected examples of associations between nervous system diseases and exposures to occupational and
environmental chemicals have been reviewed. Recent outbreaks of human neurotoxicity from both well-
known and previously unknown toxicants reemphasize the need forthe medical community to give increased
attention to chemical causes of nervous system dysfunction.
INTRODUCTION
We live in a world of chemicals. The Chemical Abstracts Service's unique
computer registry of chemicals contained over 4 million distinct chemical entities as
of November 1977 [1]. Although a majority of these chemicals are isolated from
natural products or synthesized in small quantities only for research purposes, many
are produced for widespread commercial usage, particularly as pharmaceutical,
agricultural, and industrial chemicals. Each year 500-1,000 new compounds are
produced in commercial quantities. It has been predicted that the initial inventory(to
be compiled by the Environmental Protection Agency under the 1976 Toxic
Substances Control Act) of chemical substances manufactured, imported, or pro-
cessed in the United States since January 1975 may include as many as 70,000
chemicals. Although many of these compounds are probably not harmful, we will
inevitably be exposed to some of them. Many ofthese industrial chemicals may enter
the environment as waste products discharged into the air, rivers, and lakes, and
some will eventually find their way into humans through contaminated food, water,
and air. A few have found their way into the food chain through accidental
contamination due to carelessness or ignorance and these have been responsible for
serious localized outbreaks of human poisoning. Another widespread and primary
source of human contact is occupational exposure to specific chemicals found in
industrial and commercial environments. Occupational exposure often provides an
early warning of potential hazards in the general environment.
Unfortunately, only a few chemicals have been adequately examined for their
effects on human health, particularly with respect to the more subtle, subclinical
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TABLE I
Nervous System Diseases and Associated Chemicals
Autonomic Nervous S'stem
Autonomic dysfunction:
Central Nervous System
Mental retardation:
Brain edema:
Cerebrovascular arteriosclerosis:
Dementia, presenile:
Encephalitis:
Demyelination (multifocal):
Peripheral Nervous System
Facial paralysis:
Optic neuritis:
Polyneuritis:
acrylamide; carbon disulfide; organo-phosphate
esters; thallium; mercury
carbon monoxide; dichloroethane; lead;
methylmercury
hexachlorophene; methyl bromide; triethyltin
carbon disulfide
aluminum; carbon disulfide; methylmercury
lead; methylmercury; thallium; arsine; toluene
hexachlorophene; triethyltin; tetraethyl lead
trichloroethylene
carbon disulfide; cyanide; thallium
Alkyl and aryl phosphates; Leptophos; Kepone;
DDT; acrylamide; n-hexane; methyl-n-butyl
ketone; arsenic; lead; methylmercury; thallium;
tellurium; carbon monoxide; carbon disulfide;
carbon tetrachloride; 2,4-dichlorophenoxyacetic
acid; hexachlorophene; methyl bromide; methyl
chloride; phthalate esters
effects that may result from chronic low-level exposures. The nervous system may be
particularly vulnerable to many of these exogenous chemicals.1 Selective damage to
particular areas of the nervous system has been noted with numerous toxins, and
certain groups, such as the young and the elderly, may be especially vulnerable.
An ongoing activity of the Office of Health Hazard Assessment at the National
Institute of Environmental Health Sciences is to create and maintain an open-ended
data file of associations between environmental chemicals and target organ diseases,
symptoms, and signs. This review gives some selected examples of neurotoxic effects
associated with exposure to environmental and occupational chemicals.
TYPES OF NEUROTOXIC EFFECTS
Tables 1-3, represent an abbreviated compilation ofreported associations between
human nervous system diseases (Table 1), neurological manifestations (Table 2),
behavioral symptoms (Table 3), and exposure to environmental and occupational
chemicals. Literature references will be given when some of these associations are
discussed in greater detail. In someinstances, cause and effect relationships have been
clearly established, while the evidence for other associations is limited to a few case
reports. The tables are not intended to be complete, inclusive catalogs of either
nervous system symptoms or neurotoxic chemicals, but rather to illustrate the diverse
and multiple effects that may be produced by neurotoxic compounds. The terms used
to describe the nervous system diseases and symptoms were chosen because they
appear as official medical subject headings in the National Laboratory of Medicine's
Unfortunately, a standardized battery ofsensitive screening tests fordetecting and predicting the neurotoxic effects of
chemicals does not exist at the present time.
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TABLE 2
Neurological Manifestations and Associated Chemicals
Movement Disorders
Ataxia:
Myoclonus:
Parkinsonism:
Tic (facial):
Tremor
Pathological reflexes:
Sensation Disorders
Anosmia:
Hyperesthesia:
Paresthesia:
-Sleep Disorders
Hypersomnia:
Insomnia:
Speech Disorders
(slurring of speech,
stuttering, dysarthria):
Hearing Disorders
Hearing loss:
Tinnitus:
Vision Disorders
Amblyopia:
Diplopia:
Nystagmus:
Pupil reactions (abnormal):
acrylamide; methylmercury; lead; carbon monoxide;
cyanide; dichloroethane; methyl chloride; organo-
phosphate esters; Kepone
methylmercury; thallium; dichloroethane; methyl bromide
manganese
mercury; trichloroethylene
acrylamide; aniline; lead; manganese; mercury;
ethylene dichloride; Kepone; DDT; Chlordane; Leptophos
acrylamide; hexachlorophene; n-hexane; methyl-n-butyl
ketone; lead; sulfur dioxide; toluene
cadmium; carbon disulfide; sulfur dioxide
arsenic
acrylamide; arsine; lead; manganese; methylmercury
cyanide; carbon disulfide; n-hexane; methyl-n-butyl
ketone; organo-phosphate esters
acrylamide; manganese; dichloroethane
ethylene dichloride; carbon disulfide; tetraethyl
lead; mercury; organo-phosphate esters
acrylamide; benzene; methyl bromide; methyl chloride;
methylmercury; phenylmercury; manganese; organo-
phosphate esters; Kepone
cyanide; lead; methylmercury
aniline; cyanide; toluene; organo-phosphate esters
mercury; phenylmercury; cyanide; 2,3,7,8-tetra-
chlorodibenzo-p-dioxin; organo-phosphate esters
hexachlorophene; methyl bromide; methyl chloride
ethylene dichloride; thallium; organo-phosphate esters
methylmercury; lead; thallium; organo-phosphate esters
Index Medicus. The use of these terms facilitates the computerized, on-line retrieval
of bibliographic citations from the Medline2 and Toxline3 data bases.
It is apparent from these tables, that the actions oftoxic agents on both the central
and peripheral nervous system are extremely varied and complex, and reflect a
variety of physiological and biochemical mechanisms. The compounds associated
with nervous system disorders include many different chemical structures and are
widely employed in avariety ofcommercial and industrial processes. All structures of
the nervous system may be affected, though certain anatomical areas and cell types
2Medical Literature Analysis and Retrieval System on-Line, a data base maintained by the National Library of
Medicine containing bibliographic citations from biomedical journals.
3Toxicology Information on-Line, a data base maintained by the National Library of Medicine containing references
to published human and animal toxicity studies.TABLE 3
Behavioral Symptoms and Associated Chemicals
Affective Disturbances
Euphoria/ Excitement: toluene; manganese; DDT; diethyl ether; n-hexane
Nervousness/Irritability: benzene; chloroprene; 2,3,7,8-tetrachlorodibenzo-
p-dioxin; ethylene dichloride; organo-phosphate
esters; Kepone
Depression/Anxiety: carbon disulfide; organo-phosphate esters; mercury;
carbon tetrachloride; lead; Kepone
Psychoses: organo-phosphate esters; carbon disulfide
Cognition Disorders
Mental confusion: chloroprene; toluene; methyl bromide; methyl
chloride; carbon tetrachloride;
adiponitrile; methylmercury; Kepone
Delirium/ Hallucinations: thallium; toluene; methyl chloride; dimethyl-
sulphate; acrylamide; manganese; hydroquinone
Memory disorders: manganese; toluene; methyl chloride; ethylene
dichloride; organo-phosphate esters; Kepone
appear to be more vulnerable. Some compounds act directly on the nervous system,
whereas others affect nonneuronal processes which in turn affect the nervous system.
More generalized neurotoxic effects may result from such processes as anoxia or
protein denaturation. Other neurotoxins interfere with more specific biochemical
mechanisms. In most instances, the mechanisms of human neurotoxicity remain
undefined. Peripheral neuropathy is a consequence of exposure to many chemicals,
but frequently mixed central and peripheral nervous system effects are involved.
Nervous system tumors are not listed in Table 1, since there is little concrete datafor
the environmental induction of these tumors in humans, though they can be
produced in animal studies by such compounds as nitrosoalkylureas and triazenes.
Ultimately, direct or indirect damage to the nervous system will result in functional
disturbances. Tables 2 and 3 show that sensory and motor functions, cognitive
processes such as learning and memory, arousal mechanisms, and emotional factors
may all be affected.
Unfortunately, many of the neurological and behavioral symptoms listed in Tables
2 and 3 are considered subjective, minor, ornonspecific, and can readily be attributed
to a number of other factors. It is therefore difficult to correlate such symptoms with
chemical causes unless some preliminary warning of the possible hazard has been
given. Nevertheless, such symptoms cannot be disregarded, since subtle changes in
nervous system function may precede the more overt symptoms of intoxication and
histopathological damage. Even though functional correlates ofneurotoxicity are not
easily determined and are seldom specific (just as correlates of fever, oxygen
deficiency, or gastrointestinal disturbances are nonspecific), combinations ofnonspe-
cific changes can lead to an elucidation of "syndromes" typical for a chemical or a
group of chemicals. The neurotoxicology of a few compounds listed in Tables 1-3 is
discussed in greater detail. Effects on other organ systems and theirinterrelationships
with the nervous system, though important, are not emphasized here.
INORGANIC AND ORGANO-LEAD COMPOUNDS
The neurotoxicity of inorganic lead at high doses has been well documented for
many decades. Although the occurrence of severe lead poisoning in children and
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adults is diminishing, classic symptoms of lead intoxication are still reported in
young children who chew on lead-painted objects [2,3]; in adults after the ingestion of
contaminated illicit whiskey [4-6]; and in occupationally exposed workers [5].
Encephalopathy is one of the most serious consequences of acute lead intoxication,
since permanent damage often occurs, particularly in young children [7-12]. Other
neurological symptoms following acute lead exposure include tremors, disorienta-
tion, neuropathy, aphasia, blindness, convulsions, and coma [13]. The neuropathy is
primarily a motor neuropathy, which usually shows up as wrist drop and/or foot
drop paralysis. Histologically, adults develop primary changes in the Schwann cells
with segmental disintegration beginning at the nodes of Ranvier [14,15]. Animal
studies have shown that lead produces segmental demyelination [16-18], but this has
not yet been shown concretely in humans. Peripheral neuropathy is rarely reported in
lead intoxicated children, but Feldman et al. [19] suggest that childhood neuropathy
may be overshadowed by the clinical symptoms of encephalopathy. They found
reduced motor nerve conduction velocities in children with a known history of
plumbism. More recently, it was reported that children with sickle cell disease may be
predisposed to the development oflead neuropathy [20,21]. Children with sickle cell
disease displayed motor weakness, reflex abnormalities, mild hypesthesia, and
reduced nerve conduction velocities subsequent to lead intoxication.
The possibility that continuous exposure to low levels of lead may have subtle
neurological and behavioral effects is a growing concern. Indications of subclinical
peripheral neuropathy were reported by Seppalainen et al. [22]. They observed
impaired motor nerve conduction velocities in otherwise neurologically asympto-
matic workers whose blood lead levels had not exceeded 70 .g/ 100 ml. Recently,
Lilis et al. [23] found that lead exposed workers, whose blood lead levels were lower
than 80 mg/ 100 ml and who had no history ofhigher blood lead concentrations, had
an increased incidence of such central nervous system symptoms as irritability and
sleep disturbances. However, nerve conduction velocities did not differ significantly
from the controls. It has also been a concern that chronic, asymptomatic lead
exposure may cause subtle behavioral and neurological impairment in young
children. An association between lead exposure and childhood hyperactivity was
suggested by David et al. [24]. However, it cannot be ruled out that lead absorption
was secondary to hyperactivity since disturbed children tend to exhibit an increased
incidence of pica [25,26]. The statistical treatment of this study has also been
criticized [27]. Many studies suggest an association of asymptomatic lead exposure
with mental and behavioral impairment [28-32]; but other studies have not found
such an association [33-36]. Thus the data presently available are conflicting and
inadequate to conclude that subtle psychological, emotional, and neurological
damage occurs in children as a result oflead exposure at levels below those causing
clinical symptoms. Resolution of this matter is of considerable importance.
The clinical picture of intoxication due to organo-lead compounds such as
tetraethyl lead, is quite different from that produced by inorganic lead compounds.
Tetraethyl lead can be absorbed rapidly through the skin, is soluble in central
nervous system structures, and is demethylated by liver microsomes to triethyl lead,
which is presumably thetoxicmetabolite[37]. Neurological symptoms resultingfrom
tetraethyl lead exposure range from euphoria, nervousness, insomnia, and excessive
daydreaming to hallucinations and acute psychoses, depending upon the severity and
duration of exposure [38]. These symptoms are generally reversible. Animal studies
indicate that triethyl lead is a multifocal central nervous system hypomyelinating
agent [39].
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Inhalation of elemental mercuryvapors can lead to such neurological symptoms as
slight tremor, amblyopia, insomnia, anxiety, depression, and autonomic nervous
system dysfunction[40]. Similarneurological symptoms may also result from chronic
exposure to inorganic mercury salts, but these compounds are less able to penetrate
the central nervous system and appear to exert their primary effect on the kidney
[41].
Exposure to organo-mercury compounds, particularly methylmercury, can result
in severe, irreversible damage to the central nervous system. Thousands of cases of
methylmercury intoxication were reported in Iraq in 1971-1972, when seed grain
treated with mercury-containing fungicides, was inadvertently used to make bread
[42]. Another major outbreak occurred in Japan, where mercury-containing wastes,
discharged into the waters of Minamata Bay, resulted in high methylmercury
concentrations in fish, and in the subsequent poisoning (Minamata disease) of fish-
eating families [43]. Unfortunately, methylmercury has become a fairly ubiquitous
pollutant. For example, certain populations in Canada and Sweden continue to be
exposed to methylmercury through the consumption of contaminated game fish
caught in waters polluted with mercury effluents from chloralkali plants and paper
mills [44-46].
The initial symptoms of methylmercury intoxication are primarily neurological
and behavioral, and include paresthesia, astereognosis, hearing and vision disorders,
cerebellar ataxia and dysarthria, myoclonus, irritability, and memory impairment
[47-49]. Some of these symptoms are reversible, depending upon the degree of
exposure. Thesensory deficitsgenerallyappear first. Constriction ofthe visual field is
the most common visual deficit, and it may be one of the earliest signs of chronic
methylmercury exposure in primates [50]. The motor disturbances range from
impairment offine motorcontrol to cerebellar ataxia and dysarthria. Methylmercury
causes a distinctive spread of necrosis in thegranule cell layer ofthe cerebellar cortex
and visual cerebral cortex[48]. Clinicalelectrophysiological studies have not revealed
firm evidence ofperipheral neuropathy[51]. The duration and timing ofexposure are
critical variables. Methylmercury caneasily cross theplacenta, and fetal and neonatal
exposure (via breast milk) can result in irreversible, severe neurological defects,
including mental retardation, blindness, and deafness [52].
KEPONE
It has been known for years that acute and chronic exposure to chlorinated
hydrocarbon pesticides can affect the human nervous system. The recent dramatic
example of human kepone intoxication reemphasizes the need for continuing
surveillance of the health effects of these compounds. Kepone (common name,
Chlordecone), a complex polychlorinated hydrocarbon pesticide, had been manufac-
tured invery small quantities in the United States until 1974, when a small factory in
Virginia began its mass production. More than a hundred workers were heavily
exposed, and some of their spouses and children also showed evidence of exposure.
This chemical has also polluted some Virginia waterways [53].
The workers exposed to kepone suffered severe neurological and behavioral
impairment in addition to mild liver disorders and decreased sperm production [54].
The neurological symptoms included tremors, slurred speech and stuttering, opsoclo-
nus, exaggerated startleresponse, andsigns ofcerebellardysfunction (incoordination
and gait ataxia). Behavioral symptoms included anxiety, irritability, memory distur-
bances, and hyperkinesis. Clinical symptoms of a peripheral neuropathy were
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generally not apparent and motor nerve conduction velocities were within the normal
range [55]. Histopathological studies of peripheral nerves revealed damage primarily
to the nonmyelinated and smaller myelinated nerve fibers, and suggested primary
involvement of the Schwann cells [56]. The severity of the neurological and
behavioral symptoms appears to be directly related to the degree and duration of
exposure. Symptoms may begin as early as a week after exposure, and have not
always improved after termination of exposure. Fortunately, it has recently been
shown that treatment with the drug, cholestyramine, hastens the excretion ofkepone
and decreases the severity of the symptoms [57].
ORGANO-PHOSPHATES
Organo-phosphorus (OP) esters are widely used as pesticides, and have substan-
tially replaced many of the more persistent chlorinated hydrocarbon insecticides.
Although most organo-phosphates are rapidly hydrolized and have few cumulative
ecological effects, they do produce acute toxic effects and have frequently caused
accidental fatalities in both humans and in domestic animals [58]. The toxicity is
mainly due to cholinesterase inhibition, resulting in excessive muscarinic and
nicotinic effects [59]. The central nervous system symptoms of OP intoxication
include convulsions, speech disorders, insomnia, drowsiness, coma, anxiety, irritabil-
ity, depression, impaired memory, and personality disorders [60,61]. These vary in
severity, rapidity of onset, and duration depending upon the particular OP com-
pound involved. Signs of intoxication are usually not apparent until the levels of
acetylcholinesLerase have- been reduced by at least 50%, because adaptation to low
cholinesterase levels can occur. After recovery from acute OP poisoning, certain
central nervous system effects, such as impaired memory, depression, and electro-
encephalographic changes may persist forweeks or months[62,63]. Concern has also
been raised that chronic occupational exposure to OP compounds may result in
subclinical, neurological and behavioral deficits. Abnormal electroencephalograms,
anxiety, depression, and impaired memory have been reported in otherwise asympto-
matic agricultural and industrial workers [64-67]. Other studies, however, have been
negative [68,69] and more data are necessary to resolve this important issue.
In addition to the central nervous system cholinergic effects, a small group of the
organo-phosphorus compounds produce degenerative changes in the central and
peripheral nervous system which ultimately result in a sensory-motor neuropathy.
This neuropathy does not manifest itself until several days or weeks after exposure.
This delayed neuropathy is not primarily a function of the central cholinergic
response, since most OP compounds do not cause delayed neuropathy. Once
exposure has occurred there is presently no way ofpreventing the development ofthe
neuropathy. Attention was first focused on the delayed neurotoxicity syndrome in
the United States in 1930 [70] when more than 20,000 humans developed paralysis
after accidental exposure to triorthocresyl phosphate (TOCP), an aryl phosphate
used as a lubricant and plasticizer. A second outbreak of TOCP neuropathy and
paralysis, also involving thousands of people, occurred in Morocco in 1959 [71].
Accidental exposure to the pesticides, Mipafox [72], Merphos [73], and possibly
Leptophos [74], have also resulted in some cases of delayed neuropathy in humans.
The OP delayed neurotoxicity syndrome begins one to three weeks after exposure.
Initial symptoms include paresthesia, hypesthesia, abnormal reflexes, and muscle
weakness [75,76]. Muscle weakness begins in thefeet and spreads progressively to the
legs, hands, and forearms. Mild cases usually recover, but in severe cases ataxia, and
permanent paralysis can occur. Sensory and motor nerves, the spinal cord, and
463medulla oblongata may all be damaged [78]. An accumulation of membrane-bound
vesicles within the axoplasm of motor and nerve terminals, as well as distal,
secondary demyelination have been observed[77,78]. Recent studies have shown that
the delayed neuropathy-inducing OP compounds interfere in a specific way with a
characteristic membrane-bound nerve cell protein, referred to as "neurotoxic ester-
ase" [79-82]. The precise mechanisms involved in the delayed neurotoxicity syn-
drome have not been determined.
n-HEXANE AND METHYL-n-BUTYL KETONE
Although most organic solvents are known to be central nervous system depres-
sants at high concentrations, they have generally been considered to be relatively non-
neurotoxic at low concentrations. Recently, however, several outbreaks of sensori-
motor neuropathy have been reported as a result of prolonged exposureto relatively
low levels of n-hexane and methyl-n-butyl ketone (MBK). Neuropathy due to
n-hexane (a solvent used in many industrial processes, often a major component of
glues, and a minor component of petroleum) has been reported in glue sniffers
[83-86], in shoe-industry workers [87,88], cabinet refinishers [89], and in makers of
adhesive products [90]. The neurological symptoms include paresthesia, reflex loss,
symmetrical distal ascending motor weakness, and an unsteady gait[87-90]. There is
a slowing of sensory and motor nerve conduction velocities, usually proportional to
the severity of the clinical deficits. In glue sniffers, motor impairment tends to be
more severe and muscle biopsies have shown neurogenic atrophy [83-86]. A similar
sensorimotor neuropathy has recently been reported in workers exposed to the
widely used solvent and cleaning agent, methyl-n-butyl ketone [91-95]. Clinical
symptoms again included paresthesia, mild reflex loss, progressive symmetrical distal
muscle weakness, and a slowing of motor nerve conduction velocities [91-94]. The
symptoms of n-hexane and MBK neuropathy are usually reversible, but recovery is
often slow.
Animal studies and human nerve biopsies have shown that n-hexane and MBK
cause axonal degeneration in the distal parts of vulnerable nerves. This axonal
degeneration is accompanied by a characteristic pattern ofhistopathological changes
[83,85,96,97]. These changes consist of multiple and focal, giant axonal swellings
displaying an accumulation of 10 nm neurofilaments. Neurofilament accumulation
occurs first in myelinated axons, where the swellings occur on the proximal, distal
sides of the nodes of Ranvier, but similar changes eventually occur in nonmyelinated
axons. Schaumberg and Spencer [98,99] have shown that these changes occur
concomitantly in both the central and peripheral nervous system. An accumulation
of neurofilaments within axons has also been observed in acrylamide-induced
neuropathy [100,101].
The mechanisms of axonal degeneration are unknown, but similar histopathologi-
cal changes [102,103] have been observed with 2,5-hexanedione, a metabolite ofboth
n-hexane and MBK[104,105], which suggests that there may be a common metabolic
basis for the neuropathy induced by n-hexane and MBK.
COMMENTS
The etiology of many neurological and/or psychiatric disorders is obscure or
completely unknown. Affected patients frequently have nonspecific complaints that
are easily passed off as being minor, temporary, psychosomatic, due to stress, etc.
However, these same subtle symptoms may be the first signs of intoxication with
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environmental and occupational chemicals. The medical community should become
sensitized to considering nervous system toxicants as a source of these otherwise
unexplainable symptoms, and evidence for occupational and environmental expo-
sures must be included in the differential diagnosis of neurological diseases.
The toxicity of the compounds mentioned in this review is now well known, but
they may represent only the "tip of the iceberg." The Toxic Substances Control Act
of 1976 requires that new compounds be properly tested so that their health effects
can be evaluated before human exposure occurs. The continued alertness of the
medical community to the potential chemical causes ofnervous system dysfunction is
necessary to insure that this legislation becomes effective.
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